Thomas Dubensky
Director/Board Member chez HTG MOLECULAR DIAGNOSTICS, INC.
Fortune : 443 171 $ au 31/03/2024
Profil
Dr. Thomas W.
Dubensky is a President, Chief Executive Officer & Director at ImmuneSensor Therapeutics, Inc. He is on the Board of Directors at ImmuneSensor Therapeutics, Inc. and HTG Molecular Diagnostics, Inc. Dr. Dubensky was previously employed as a President & Director by Tempest Therapeutics, Inc., a President & Director by TempestTx, Inc., a Chief Scientific Officer by Aduro BioTech, Inc., a Chief Scientific Officer by Anza Therapeutics, Inc., a Vice President-Research by Cerus Corp., a Scientific Director by Chiron Corp., a Principal by Chiron Viagene, Inc., a Chief Scientific Officer by Immune Design Corp., and a Vice President by Onyx Pharmaceuticals, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from the University of Colorado Health Sciences Center.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2023 | 113 343 ( 0,51% ) | 443 171 $ | 31/03/2024 |
Postes actifs de Thomas Dubensky
| Sociétés | Poste | Début |
|---|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Director/Board Member | 18/08/2022 |
ImmuneSensor Therapeutics, Inc.
 ImmuneSensor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneSensor Therapeutics, Inc. is a clinical-stage biotechnology company based in Dallas, TX. ImmuneSensor Therapeutics is building a pipeline of novel small molecule and adc immune stimulating candidates that aim to modulate the innate immune system. The company is led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. ImmuneSensor Therapeutics is focused on discovering and developing novel therapies that leverage the incredible versatility and therapeutic potential of the cgas-sting pathway, which is one of the key pathways in the innate immunity system that works to detect both foreign and host-derived DNA. The company was founded in 2014 by Zhijian Chen and Jet Li, and the CEO is Ernest Wong. | Chief Executive Officer | 01/05/2024 |
Anciens postes connus de Thomas Dubensky
| Sociétés | Poste | Fin |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | President | 15/09/2023 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/08/2017 |
| CERUS CORPORATION | Chief Tech/Sci/R&D Officer | 16/11/2007 |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Chiron Viagene, Inc.
 Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Corporate Officer/Principal | - |
Formation de Thomas Dubensky
| University of California, Berkeley | Undergraduate Degree |
| University of Colorado Health Sciences Center | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CERUS CORPORATION | Health Technology |
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
ImmuneSensor Therapeutics, Inc.
ImmuneSensor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneSensor Therapeutics, Inc. is a clinical-stage biotechnology company based in Dallas, TX. ImmuneSensor Therapeutics is building a pipeline of novel small molecule and adc immune stimulating candidates that aim to modulate the innate immune system. The company is led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. ImmuneSensor Therapeutics is focused on discovering and developing novel therapies that leverage the incredible versatility and therapeutic potential of the cgas-sting pathway, which is one of the key pathways in the innate immunity system that works to detect both foreign and host-derived DNA. The company was founded in 2014 by Zhijian Chen and Jet Li, and the CEO is Ernest Wong. | Commercial Services |
